- Home
- PAA vs MRNA Comparison
PAA vs MRNA Comparison
Compare PAA & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAA
- MRNA
- Stock Information
- Founded
- PAA 1981
- MRNA 2010
- Country
- PAA United States
- MRNA United States
- Employees
- PAA N/A
- MRNA N/A
- Industry
- PAA Natural Gas Distribution
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PAA Energy
- MRNA Health Care
- Exchange
- PAA Nasdaq
- MRNA Nasdaq
- Market Cap
- PAA 12.1B
- MRNA 10.6B
- IPO Year
- PAA N/A
- MRNA 2018
- Fundamental
- Price
- PAA $18.44
- MRNA $25.90
- Analyst Decision
- PAA Buy
- MRNA Hold
- Analyst Count
- PAA 13
- MRNA 19
- Target Price
- PAA $20.67
- MRNA $48.13
- AVG Volume (30 Days)
- PAA 3.0M
- MRNA 10.5M
- Earning Date
- PAA 08-01-2025
- MRNA 07-31-2025
- Dividend Yield
- PAA 8.22%
- MRNA N/A
- EPS Growth
- PAA N/A
- MRNA N/A
- EPS
- PAA 0.93
- MRNA N/A
- Revenue
- PAA $50,089,000,000.00
- MRNA $3,177,000,000.00
- Revenue This Year
- PAA N/A
- MRNA N/A
- Revenue Next Year
- PAA $18.70
- MRNA $9.87
- P/E Ratio
- PAA $19.86
- MRNA N/A
- Revenue Growth
- PAA 3.56
- MRNA N/A
- 52 Week Low
- PAA $15.58
- MRNA $23.15
- 52 Week High
- PAA $21.00
- MRNA $138.07
- Technical
- Relative Strength Index (RSI)
- PAA 65.35
- MRNA 46.10
- Support Level
- PAA $17.66
- MRNA $25.06
- Resistance Level
- PAA $18.84
- MRNA $28.72
- Average True Range (ATR)
- PAA 0.44
- MRNA 1.18
- MACD
- PAA 0.15
- MRNA -0.18
- Stochastic Oscillator
- PAA 83.19
- MRNA 20.34
About PAA Plains All American Pipeline L.P.
Plains All American Pipeline LP through its subsidiaries, engages in the pipeline transportation, terminaling, storage, and gathering of crude oil and natural gas liquids (NGL) in the United States and Canada. The company operates through two segments, Crude Oil and NGL. The Crude Oil segment offers gathering and transporting crude oil through pipelines, gathering systems, trucks, and barges or railcars. The NGL segment is involved in natural gas processing and NGL fractionation, storage, transportation, and terminalling. It generates the majority of its revenue from the Crude Oil segment.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.